Long-term follow-up of primary and secondary prevention implantable cardioverter defibrillator patients

Guido H. van Welsenes[1], Johannes B. van Rees[1], C. Jan Willem Borleffs[1], Suzanne C. Cannegieter[2], Jeroen J. Bax[1], Lieselot van Erven[1], and Martin J. Schalij[1]*

[1]Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands; and [2]Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands

Aims	The beneficial effects of implantable cardioverter defibrillators (ICDs) in primary and secondary prevention patients are well established. However, data on potential differences between both groups in mortality and ICD therapy rates during long-term follow-up are scarce. The aim of the study was to assess differences in mortality and ICD therapy between secondary and primary prevention ICD recipients.
Methods and results	With the exception of patients with congenital monogenetic cardiac disease, all patients treated with an ICD, regardless of the underlying cardiac pathology, from 1996 to 2008 at the Leiden University Medical Center were included in the current analysis. The study population was grouped by the type of prevention (secondary or primary) for sudden cardiac death. The primary endpoint was all-cause mortality. The secondary endpoint was the occurrence of device therapy (appropriate or inappropriate). A total of 2134 (80% men, mean age 63 ± 12 years) ICD recipients were included. Of these, 1302 (61%) patients received an ICD for primary prevention of sudden cardiac death and 832 (39%) patients for secondary prevention. During a mean follow-up of 3.4 ± 2.8 years, 423 (20%) patients died. The 5-year cumulative incidence of mortality was 25% [95% confidence intervals (CI): 21−29%] for primary prevention patients and 23% (95% CI: 20−26%) for secondary prevention patients. Secondary prevention patients exhibited a 74% increased risk for appropriate therapy when compared with primary prevention patients [hazard ratios (HR): 1.7; $P < 0.001$]. A comparable risk for inappropriate shocks was observed (HR: 1.0; $P = 0.9$).
Conclusion	During long-term follow-up, primary prevention patients exhibited a lower risk of appropriate therapy, but comparable mortality rates were observed between both groups. Both groups showed similar occurrence of inappropriate shocks.
Keywords	Implantable cardioverter defibrillator • Secondary prevention • Primary prevention • Mortality • Ventricular arrhythmia

Introduction

Sudden cardiac death, mainly caused by ventricular arrhythmias (VAs) in a population with coronary artery disease, is a major cause of mortality in the western world. In the USA, the annual incidence of sudden cardiac death varies from 200 000 to 450 000 subjects.[1−4] Initially, large trials proved the effectiveness of implantable cardioverter defibrillator (ICD) treatment in survivors of life-threatening VAs such as ventricular fibrillation or ventricular tachycardia (secondary prevention).[5−7] Since survival rates of VA, prior to ICD implantation, are low, focus shifted to the identification of patients at risk of VA (primary prevention).[1] Randomized trials tested the hypothesis that ICD treatment was beneficial in a population characterized by depressed left ventricular ejection fraction (LVEF) without prior cardiac arrest and demonstrated a reduction in all-cause mortality.[8−11] Not only

---

did the implementation of these results in the international guidelines dramatically increase the number of implantations worldwide, it also changed the ICD-treated population from VA survivors to patients characterized by decreased LVEF and symptomatic or asymptomatic heart failure.[12] It is therefore important in follow-up studies to clearly describe the population currently receiving ICD treatment and to assess differences between secondary and primary prevention ICD recipients. Previous studies have clearly shown a higher occurrence of VA, causing appropriate device therapy, in secondary prevention ICD patients when compared with primary prevention ICD patients. However, data on potential differences in mortality and inappropriate ICD shocks during long-term follow-up are scarce.

Since 1996, all ICD recipients in the Leiden University Medical Center have been assessed and followed up. This cohort allows the evaluation of the long-term outcome in these two groups of patients.

Methods

Patient population

Since 1996, all patients who received an ICD in the Leiden University Medical Center have been registered in the departmental Cardiology Information System (EPD-Vision®, Leiden University Medical Center). Characteristics at baseline and data of all follow-up visits are recorded. Eligibility for ICD implantation is based on the international guidelines which, due to evolving guidelines, may have changed over time.[4,12] For the current study, all ICD-treated patients up to January 2008 were included. Patients with congenital monogenetic cardiac disease, such as hypertrophic obstructive cardiomyopathy, long-QT syndrome, Brugada syndrome, and idiopathic ventricular fibrillation, related to an increased risk of cardiac arrhythmia were excluded.[13]

The study population was grouped by type of prevention (secondary or primary) for sudden cardiac death. Prevention was defined secondary after survival of an episode of cardiac arrest, occurrence of VA with loss of consciousness or VA lasting longer than 30 s.[5,6] Prevention was considered primary in the case of depressed LVEF without prior sustained VA.[8,9,11,12]

Device implantation and programming

All implantations were carried out in the catheterization laboratory, and all devices were implanted transvenously without thoracotomy. Ventricular and atrial (pacing and shock) leads were positioned conventionally. For implantation of a cardiac resynchronization therapy—defibrillator, a coronary sinus venogram was obtained using a balloon catheter, followed by insertion of the left ventricular pacing lead into one of the posterolateral veins through an 8 Fr guiding catheter. During implantation, sensing and pacing thresholds were tested and defibrillation threshold testing was performed. Implanted systems were manufactured by Biotronik (Berlin, Germany), Medtronic (Minneapolis, MN, USA), Boston Scientific [Natick, MA, USA, formerly CPI, Guidant (St. Paul, MN, USA)], and St. Jude Medical/Ventritex (St. Paul, MN, USA). All devices were programmed with three consecutive zones: a monitor zone (150–188 b.p.m.), an antitachycardia pacing (ATP) shock zone (188–210 b.p.m.), and an initial shock zone (≥210 b.p.m.). In the monitor zone, no therapy was programmed unless slow VA was detected during follow-up. In the ATP-shock zone, arrhythmias were initially attempted to be terminated by two bursts of ATP and, if the arrhythmia continued, defibrillator shocks were used. In the case of VA faster than 210 b.p.m., device shocks were the initial therapy. Furthermore, atrial arrhythmia detection was set to >170 b.p.m. with supraventricular tachycardia discriminators enabled.

Follow-up and device interrogation

Implantable cardioverter defibrillator-treated patients were periodically seen at the outpatient clinic every 3–6 months, which included device interrogation. Printouts were checked for appropriate and inappropriate therapy (ATP and shocks). Adjudication of the delivered therapy was performed by a trained electrophysiologist. Unscheduled device interrogations were performed in the case of symptomatic episodes of arrhythmia and during unplanned hospitalization.

The last follow-up data were acquired in February 2009. Patients with >6 months of missing data were considered lost to follow-up.

Endpoints

All-cause mortality was considered the primary endpoint. Implantable cardioverter defibrillator therapies were classified appropriate when they occurred in response to ventricular tachycardia or ventricular fibrillation (secondary endpoint) and inappropriate when triggered by sinus or supraventricular tachycardia, T-wave over sensing, or electrode dysfunction (tertiary endpoint).

Furthermore, the risk for subsequent VA after the first experienced VA was assessed and compared between both subgroups. By definition, secondary prevention patients had experienced a VA prior to ICD implantation and primary prevention patients had not. Therefore, to evaluate differences in the risk for subsequent VA, the risk of a first appropriate shock in secondary prevention patients was compared with the risk of a second appropriate shock in primary prevention patients.

Statistical analysis

Continuous data are expressed as mean ± standard deviation; categorical data are presented as numbers and percentages. Differences at baseline were evaluated with the independent-sample t-test for continuous variables and χ^2 test for categorical variables. Cumulative incidences were analysed by the method of Kaplan–Meier and compared using the log-rank test. The 95% confidence intervals (CI) were calculated as 1.96 times the standard error in each direction. The relation between baseline characteristics and endpoints was assessed by using Cox regression analysis and described with hazard ratios (HR) and 95% CI. In the multivariate Cox regression analysis for all-cause mortality, adjustments were made for age, gender, QRS-duration, New York Heart Association (NYHA) functional class, renal function, LVEF, and history of atrial fibrillation.[14,15] For all tests, a P-value of <0.05 was considered significant.

Results

Baseline

A total of 2471 patients received ICD treatment during the study period. Of the total, 206 (8%) patients were diagnosed with a congenital monogenetic cardiac disease. Of the total, 131 (5%) patients were lost to follow-up, of whom 52 (40%) patients received an ICD for secondary prevention, and 79 (60%) patients for primary prevention. The remaining 2134 patients were considered the study population and had a mean follow-up duration of 3.4 ± 2.8 years.

The study population was, as mentioned above, grouped by the type of prevention (secondary or primary) for sudden cardiac death. Of these, 1302 (61%) patients received an ICD for primary prevention and the remaining 832 (39%) patients for secondary prevention. Primary prevention patients had a mean follow-up duration of 2.5 ± 2.0 years and secondary prevention patients a mean follow-up duration of 4.9 ± 3.3 years. As can be seen in *Table 1*, comparison of the two groups revealed in the primary prevention group a higher NYHA functional class (mean NYHA: 2.3 ± 0.8 vs. 1.8 ± 0.8; $P < 0.001$), a wider QRS complex (mean QRS: 130 ± 3 vs. 120 ± 32 ms; $P < 0.001$), and a lower LVEF (mean LVEF: 29 ± 12 vs. 37 ± 15; $P < 0.001$).

All-cause mortality

During follow-up, 423 (20%) patients died. The cumulative incidence for all-cause mortality was 6% (95% CI: 5−7%) at 1 year, 16% (95% CI: 14−17%) at 3 years, and 25% (95% CI: 22−28%)

Table I Baseline characteristics of primary vs. secondary prevention implantable cardioverter defibrillator patients

	Primary (n = 1302)	Secondary (n = 832)	P-value
Clinical parameters			
Male gender	1035 (80%)	680 (82%)	0.204
Age (years)	63 ± 11	63 ± 13	0.459
Ischaemic heart disease	881 (68%)	605 (73%)	0.020
NYHA functional class			<0.001
I	245 (19%)	372 (45%)	
II	486 (37%)	288 (34%)	
III	529 (41%)	158 (19%)	
IV	42 (3%)	14 (2%)	
QRS duration (ms)	130 ± 35	120 ± 32	<0.001
Renal clearance (mL/min)[a]	78 ± 36	79 ± 38	0.791
LVEF (%)	29 ± 12	37 ± 15	<0.001
History of atrial fibrillation	347 (27%)	173 (21%)	0.002
Type of device			
Single-chamber	36 (5%)	219 (26%)	<0.001
Dual-chamber	517 (40%)	487 (59%)	
CRT-D	722 (55%)	126 (15%)	
Medication			
Beta-blockers	830 (64%)	337 (41%)	<0.001
ACE-inhibitor/AT antagonist	1100 (85%)	569 (68%)	<0.001
Diuretics	975 (75%)	429 (52%)	<0.001
Amiodarone	117 (14%)	226 (27%)	<0.001
Statins	864 (66%)	436 (52%)	<0.001

ACE, angiotension-converting enzyme; AT, angiotensin; CRT-D, cardiac resynchronization therapy-defibrillator; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.
[a]Renal clearance was determined with the formula of Cockcroft−Gault.

at 5 years. Comparison between the two groups demonstrated a higher but not statistically significant cumulative incidence for all-cause mortality for primary prevention patients when compared with secondary prevention patients during follow-up (*Figure 1*); at 5 years of follow-up, the incidence was, respectively, 25% (95% CI: 21−29%) vs. 23% (95% CI: 20−26%). As can be seen in *Figure 1*, during the first 3 years of follow-up, differences in mortality rates between both groups increased, whereas after 3 years the differences in mortality rates remained stable. The risk for all-cause mortality was higher for primary prevention patients than for secondary prevention patients, but did not reach significance (HR: 1.2 95% CI: 1.0−1.5) after 5 years of follow-up ($P = 0.05$). Moreover, multivariate Cox regression analysis demonstrated that after adjustment for age, gender, QRS duration, NYHA functional class, renal function, LVEF, and history of atrial fibrillation, primary prevention patients exhibited a similar risk for death when compared with secondary prevention patients (HR: 1.1 95% CI: 0.8−1.4; $P = 0.6$).

Appropriate therapy

Ventricular arrhythmia triggered appropriate therapy (ATP or shock) in 674 (32%) patients. A total of 1529 episodes of VA were terminated by ICD shocks in 423 (20%) patients. Appropriate ATP ended VA in 14 006 episodes in 466 (22%) patients. Cumulative incidence for appropriate therapy was 18% (95% CI: 16−19%) at 1 year, 33% (95% CI: 31−35%) at 3 years, and 43% (95% CI: 40−46%) at 5 years. Comparison between the two study groups demonstrated a cumulative 5-year incidence for appropriate therapy of 37% (95% CI: 33−42%) for primary prevention patients and 51% (95% CI: 47−55%) for secondary prevention patients (*Figure 2*). Cox regression analysis demonstrated a 74% increased risk of appropriate therapy in the secondary prevention group when compared with the primary prevention group (HR: 1.7, 95% CI: 1.5−2.0; $P < 0.001$).

Cumulative incidence for appropriate shock only was 28% (95% CI: 25−31%) at 5 years. For primary prevention patients, the


Figure I All-cause mortality. Kaplan−Meier curves of all-cause mortality for primary and secondary prevention implantable cardioverter defibrillator recipients. In the parenthesis, next to patients at risk, the yearly incidences (%) per corresponding time point are noted.

Figure 2 Appropriate therapy. Kaplan–Meier curves of appropriate therapy for primary and secondary prevention implantable cardioverter defibrillator recipients.


Figure 3 Appropriate shocks. Kaplan–Meier curves of appropriate shocks for primary and secondary prevention implantable cardioverter defibrillator recipients.

Figure 4 Subsequent risk for appropriate shock. Kaplan–Meier curves of appropriate shock for the second appropriate shock in primary prevention implantable cardioverter defibrillator recipients and the first appropriate shock in secondary prevention implantable cardioverter defibrillator recipients.


Figure 5 Inappropriate shocks. Kaplan–Meier curves of inappropriate shocks in primary and secondary prevention implantable cardioverter defibrillator recipients.

5-year cumulative incidence for appropriate shocks was 20% (95% CI: 16–23%) when compared with 37% (95% CI: 33–41%) for secondary prevention patients (*Figure 3*). Secondary prevention patients exhibited more than double the risk for appropriate shocks during long-term follow-up (HR: 2.3, 95% CI: 1.9–2.9; *P* < 0.001).

Risk for subsequent appropriate shock

In the primary prevention group, 141 (11%) patients received appropriate shocks. Of these 141 patients, 49 (35%) patients experienced a second appropriate device shock 275 ± 455 days after the first episode. As can be seen in *Figure 4*, the 5-year cumulative incidence of a second appropriate device shock in primary prevention patients was 50% (95% CI: 38–62%), and the cumulative incidence of a first appropriate shock in secondary prevention patients was 37% (95% CI: 33–41%). Comparison of these groups demonstrated that primary prevention ICD recipients have twice the risk for a subsequent appropriate shock when compared

with a first appropriate shock in the secondary prevention group (HR: 2.0, 95% CI: 1.5–2.7; *P* < 0.001).

Inappropriate shocks

During follow-up, 241 (14%) patients experienced inappropriate device discharges with a mean number of 2.9 ± 4.5 shocks. Cumulative incidence for inappropriate shocks was 7% (95% CI: 6–8%) at 1 year, 13% (95% CI: 11–14%) at 3 years, and 17% (95% CI: 15–19%) at 5 years. As can be seen in *Figure 5*, the comparison between the two study groups demonstrated a cumulative 5-year incidence for inappropriate shocks of 18% (95% CI: 14–21%) for primary prevention patients and 17% (95% CI: 14–20%) for secondary prevention ICD patients. Cox regression analysis showed a comparable risk of experiencing an inappropriate shock between the two groups (HR: 1.0, 95% CI: 0.8–1.3; *P* = 0.9).

Discussion

The main findings of the current study on the 5-year outcome of primary and secondary prevention ICD patients can be summarized as follows: (i) patients treated for secondary prevention experienced appropriate therapy more often; (ii) the long-term risk for all-cause mortality was comparable for both groups; (iii) risk for subsequent VA was higher in primary prevention patients than in secondary prevention patients; and (iv) no differences were demonstrated in the incidence of inappropriate shocks.

Previously executed large randomized trials have proved the beneficial effect of ICD treatment for primary and secondary prevention of sudden cardiac death. These trials, however, required specific patient criteria for inclusion and might, therefore, not be representative for the overall population presently considered for ICD treatment. The current study is of additive value to the current literature since it assesses long-term follow-up in a large population of primary and secondary prevention ICD recipients in general practice, outside the setting of a clinical trial.

Survival in implantable cardioverter defibrillator recipients

Large randomized clinical trials for primary and secondary prevention have demonstrated improved survival in patients treated with ICD therapy.[8–11,16] The first trials on the secondary prevention of sudden cardiac death reported all-cause mortality rates ranging from 16 to 36% over 18 to 57 months, respectively.[5–7] Primary prevention trials, on the other hand, demonstrated mortality incidences ranging from 14 to 23% over 20 to 39 months of follow-up, respectively.[8–11,17] In the current study, comparable mortality rates were observed. During long-term follow-up of 5 years, 23% of secondary prevention patients died when compared with 25% of primary prevention patients. Considering the different clinical characteristics at baseline, one should expect higher mortality rates for primary prevention ICD patients. After all, primary prevention ICD patients have more advanced heart disease and more coexisting co-morbidity, which is in line with previous clinical trials.[5,7,9–11,16,17] Undisputedly, these characteristics are related to an increased risk for non-arrhythmic death. In contrast, secondary prevention ICD recipients exhibited a higher risk of experiencing life-threatening arrhythmic events than primary prevention patients, as can be concluded from higher incidences of appropriate device therapy.[18] Since ICDs extend survival only in the case of VA and not in the case of non-arrhythmic events, one might expect higher all-cause mortality rates in primary prevention patients. It is therefore interesting, that in the current study, this thesis was not confirmed. Inaccuracy due to the smaller number of primary prevention patients with long-term follow-up could be an explanation, since initially the mortality curves were divergent (up to 3 years of follow-up). Another explanation could be the supposed negative impact of appropriate shocks on mortality (HR: 2.2; $P < 0.001$).[19] As demonstrated, secondary prevention patients exhibit a 74% increased risk for appropriate therapy and accordingly this might affect the mortality curve of the secondary prevention group more than it affects the curve of the primary prevention group.

Occurrence of appropriate and inappropriate implantable cardioverter defibrillator therapy

Germano et al.[18] evaluated the incidence of appropriate therapy in seven major primary and secondary prevention ICD trials and reported appropriate ICD therapy rates ranging from 54% during 45 months of follow-up to 64% during 36 months of follow-up in secondary prevention trials. In primary prevention trials, lower incidences were reported ranging from 17% over 29 months of follow-up to 31% over 24 months of follow-up in primary prevention trials.[18] These results were in line with the observed cumulative incidences in the current study. As expected, the prevalence of appropriate ICD therapy was highest in survivors of life-threatening arrhythmias.

In the current study, inappropriate shocks were relatively common in both groups of ICD recipients, occurring in 18% of primary prevention patients and in 17% of secondary prevention patients after 5 years of follow-up. Comparable findings were observed in the review by Germano et al.[18] It should be noted that both groups had a similar risk for experiencing inappropriate shocks. Previously reported studies in the literature characterize patients who experience inappropriate shocks as younger patients with non-ischaemic heart disease, and a history of atrial fibrillation and smoking.[20–23] Unlike with the occurrence of VA, for which poor cardiac function predicts well, inappropriate shocks occur mainly due to erroneous discrimination of supraventricular arrhythmias or abnormal sensing by the algorithms within the ICD.[24,25] Therefore, criteria for the classification of primary and secondary prevention (i.e. depressed LVEF or prior life-threatening VA) do not predispose for the occurrence of inappropriate shocks.

Limitations

This was a prospective observational study performed to assess differences between primary and secondary prevention ICD patients. Since patients were collected over a long period of time, evolving guidelines could have created a heterogeneous population.

Conclusion

During long-term follow-up, compared with secondary prevention ICD patients, primary prevention ICD recipients exhibited a lower risk of VA, which triggered appropriate ICD therapy but demonstrated comparable mortality rates. Both groups showed a similar occurrence of inappropriate shocks.

References

1. de Vreede-Swagemakers JJ, Gorgels AP, Dubois-Arbouw WI, van Ree JW, Daemen MJ, Houben LG et al. Out-of-hospital cardiac arrest in the 1990's: a population-based study in the Maastricht area on incidence, characteristics and survival. *J Am Coll Cardiol* 1997;**30**:1500–5.
2. Podrid PJ, Myerburg RJ. Epidemiology and stratification of risk for sudden cardiac death. *Clin Cardiol* 2005;**28**:I3–11.

3. Zipes DP, Wellens HJ. Sudden cardiac death. *Circulation* 1998;**98**:2334−51.

4. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M *et al.* ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). *J Am Coll Cardiol* 2006;**48**:e247−346.

5. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. *N Engl J Med* 1997;**337**:1576−83.

6. Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS *et al.* Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. *Circulation* 2000;**101**:1297−302.

7. Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). *Circulation* 2000;**102**:748−54.

8. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R *et al.* Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. *N Engl J Med* 2005;**352**:225−37.

9. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. *N Engl J Med* 1999;**341**:1882−90.

10. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H *et al.* Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. *N Engl J Med* 1996;**335**:1933−40.

11. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS *et al.* Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. *N Engl J Med* 2002;**346**:877−83.

12. Epstein AE, Dimarco JP, Ellenbogen KA, Estes NA III, Freedman RA, Gettes LS *et al.* ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. *J Am Coll Cardiol* 2008;**51**:e1−62.

13. Dimarco JP. Implantable cardioverter-defibrillators. *N Engl J Med* 2003;**349**:1836−47.

14. Tandri H, Griffith LS, Tang T, Nasir K, Zardkoohi O, Reddy CV *et al.* Clinical course and long-term follow-up of patients receiving implantable cardioverter-defibrillators. *Heart Rhythm* 2006;**3**:762−8.

15. Borleffs CJ, van Welsenes GH, van Bommel RJ, van der Velde ET, Bax JJ, van Erven L *et al.* Mortality risk score in primary prevention implantable cardioverter defibrillator recipients with non-ischaemic or ischaemic heart disease. *Eur Heart J* 2010;**31**:712−8.

16. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP *et al.* Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. *Eur Heart J* 2000;**21**:2071−8.

17. Bigger JT Jr. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. *N Engl J Med* 1997;**337**:1569−75.

18. Germano JJ, Reynolds M, Essebag V, Josephson ME. Frequency and causes of implantable cardioverter-defibrillator therapies: is device therapy proarrhythmic? *Am J Cardiol* 2006;**97**:1255−61.

19. Poole JE, Johnson GW, Hellkamp AS, Anderson J, Callans DJ, Raitt MH *et al.* Prognostic importance of defibrillator shocks in patients with heart failure. *N Engl J Med* 2008;**359**:1009−17.

20. Daubert JP, Zareba W, Cannom DS, McNitt S, Rosero SZ, Wang P *et al.* Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. *J Am Coll Cardiol* 2008;**51**:1357−65.

21. Alter P, Waldhans S, Plachta E, Moosdorf R, Grimm W. Complications of implantable cardioverter defibrillator therapy in 440 consecutive patients. *Pacing Clin Electrophysiol* 2005;**28**:926−32.

22. Goldenberg I, Moss AJ, McNitt S, Zareba W, Daubert JP, Hall WJ *et al.* Cigarette smoking and the risk of supraventricular and ventricular tachyarrhythmias in high-risk cardiac patients with implantable cardioverter defibrillators. *J Cardiovasc Electrophysiol* 2006;**17**:931−6.

23. Theuns DA, Klootwijk AP, Simoons ML, Jordaens LJ. Clinical variables predicting inappropriate use of implantable cardioverter-defibrillator in patients with coronary heart disease or nonischemic dilated cardiomyopathy. *Am J Cardiol* 2005;**95**:271−4.

24. Wilkoff BL, Hess M, Young J, Abraham WT. Differences in tachyarrhythmia detection and implantable cardioverter defibrillator therapy by primary or secondary prevention indication in cardiac resynchronization therapy patients. *J Cardiovasc Electrophysiol* 2004;**15**:1002−9.

25. Wathen MS, Degroot PJ, Sweeney MO, Stark AJ, Otterness MF, Adkisson WO *et al.* Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results. *Circulation* 2004;**110**:2591−6.